THE CLINICAL SIGNIFICANCE OF DETECTING GENITAL MYCOPLASMAS AND THE CURRENT INDICATORS OF ANTIBIOTIC SUSCEPTIBILITY OF UREAPLASMA AND M. HOMINIS


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Objective. To determine the detection rate of M. hominis, U. urealyticum, and U. parvum in patients with clinical and/or laboratory signs of inflammatory processes in the urogenital tract and in clinically healthy individuals; to study the indicators of antibiotic susceptibility of genital mycoplasma isolates. Subjects and methods. 409 patients, in whom a polymerase chain reaction and culture identified genital mycoplasmas, were examined. The susceptibility of the isolates to doxycycline, josamycin, tetracycline, ofloxacin, clindamycin, azithromycin, and erythromycin was studied. Results. U. urealyticum as monoinfection (n = 78; 39.6%) and association with U. parvum (n = 43; 21.8%) and M. hominis (n = 32; 16.2%) was significantly more frequently found in the patients with inflammatory diseases of the urogenital system than in the clinically healthy individuals (n = 10; 4.7%, n = 20; 9.4%, and n = 12; 5.7%, respectively). In male patients, the infectious inflammatory process manifested as urethritis; the pattern of genital mycoplasmas was characterized by a preponderance of U. urealyticum (46.9%), including that in association with U. parvum (31.25%). In female patients, U. urealyticum significantly prevailed over the other Mycoplasma species and were detected in 37.5% of patients with vaginitis, in 47.6% of those with cervicitis, and in 37.2% of those with vaginitis concurrent with urethritis or cervicitis (p<0.05). Infection with U. urealyticum, including that in association with U. parvum was more commonly accompanied by a high leukocyte reaction (52.4-74.3%; p < 0.05) than infection with M. hominis and U. parvum. Ureaplasma and M. hominis demonstrated a low level of antimicrobial resistance to doxycycline (2.8% and 3.4%, respectively), josamycin (7.8% and 5.1%), tetracycline (9.2% and 5.1%) and a high rate of resistance to erythromycin (75.2% and 71.4%, respectively), azithromycin (64.2% and 62.8%) and clindamycin (70.2% and 69.1%). Conclusion. In this study, U. urealyticum as monoinfection and in association with U. parvum was the most clinically significant etiologic agent in the development of infectious inflammatory diseases of the genitourinary system. The high susceptibility of genital mycoplasmas to doxycycline, josamycin, and tetracycline determines the possibility of their use in the therapy of urogen ital tract diseases caused by genital mycoplasmas.

Texto integral

Acesso é fechado

Sobre autores

Margarita Rakhmatulina

Email: ra.marg@yandex.ru
MD, professor of dermatology and cosmetology with the rate of clinical laboratory diagnostics, A.I. Burnazyan Federal Medical Biophysical Center, Federal Biomedical Agency of Russia. 123098, Russia, Moscow, Marshala Novikova str. 23

Alla Shashkova

Head of the outpatient department of the Astrakhan Regional Dermatovenereology Dispensary 414042, Russia, Astrakhan, M. Maksakova str. 6

Bibliografia

  1. Zdrodowska-Stefanow B., Klosowska W.M., Ostaszewska-Puchalska I., Bulhak-Koziol V., Kotowicz B. Ureaplasma urealyticum and Mycoplasma hominis infection in women with urogenital diseases. Adv. Med. Sci. 2006; 51: 250-3.
  2. Nunez-Troconis J.T. Mycoplasma hominis and Ureaplasma urealyticum in different gynecologic diseases. Invest. Clin. 1999; 40(1): 9-24.
  3. Shigehara K., Kawaguchi S., Sasagawa T., Furubayashi K., Shimamura M., Maeda Y. et al. Prevalence of genital Mycoplasma, Ureaplasma, Gardnerella, and human papillomavirus in Japanese men with urethritis, and risk factors for detection of urethral human papillomavirus infection. J. Infect. Chemother. 2011; 17(4): 487-92.
  4. Yokoi S., Maeda S., Kubota Y., Tamaki M., Mizutani K., Yasuda M. et al. The role of Mycoplasma genitalium and Ureaplasma urealyticum biovar 2 in postgonococcal urethritis. Clin. Infect. Dis. 2007; 45(7): 866-71.
  5. Naessens A. Les infections a Ureaplasma urealyticum. Acta Urol. Belg. 1993; 61(1-2): 153-6.
  6. Perzigian R.W., Adams J.T., Weiner G.M., Dipietro M.A., Blythe L.K., Pierson C.L., Faix R.G. Ureaplasma urealyticum and chronic lung disease in very low birth weight infants during the exogenous surfactant era. Pediatr. Infect. Dis. J. 1998; 17(7): 620-5.
  7. Рахматулина М.Р. Тактика диагностики и терапии урогенитальной микоплазменной инфекции согласно Федеральным клиническим рекомендациям. Фарматека. 2016; 3: 33-8. [Rakhmatulina M.R. Tactics diagnosis and treatment of urogenital mycoplasma infection in accordance with the Federal clinical recommendations. Farmateka. 2016; 3: 33-8. (in Russian)]

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2016

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies